T. Rowe Price Associates
AYTU icon

T. Rowe Price Associates’s AYTU BioPharma AYTU Stock Holding History

T. Rowe Price Associates’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-166
Closed -$40K – 2668
2020
Q3 		$40K Buy
+166
New +$42.7K ﹤0.01% 2557

Other funds holding AYTU

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $102M AUM 0.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

T. Rowe Price Associates's AYTU Position: Q4 2020 in Review

T. Rowe Price Associates sold out of AYTU BioPharma (AYTU) in Q4 2020, closing a stake of 166 shares — an estimated $40K sold.

T. Rowe Price Associates first reported a position in AYTU in Q3 2020 and held it in 1 quarter. The position peaked at $40K in Q3 2020. 42 funds tracked by Wall St. Rank hold AYTU as of Q4 2020.

  • T. Rowe Price Associates reported no remaining AYTU BioPharma position as of Q4 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 166 AYTU BioPharma shares in Q4 2020, an estimated $40K.
  • T. Rowe Price Associates first reported a position in AYTU BioPharma in Q3 2020 and held it in 1 quarter.
  • T. Rowe Price Associates's AYTU BioPharma position peaked at $40K in Q3 2020.
  • 42 funds tracked by Wall St. Rank held AYTU BioPharma as of Q4 2020.

Based on T. Rowe Price Associates's 13F filing for Q4 2020, filed 16 Feb 2021.